Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine vs nalbuphine to reduce emergence agitation after pediatric tonsillectomy/adenoidectomy
ChiCTR2400092265Phase 2Not yet recruiting
- Sponsor
- Shanghai Children's Hospital
- Start
- Nov 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial in Emergence agitation (EA), postoperative pain, postoperative nausea and vomiting (PONV) and 2 more comparing Nalbuphine + sugammadex, Nalbuphine + neostigmine + atropine and Intranasal dexmedetomidine + sugammadex (3 arms). Primary endpoint: Emergence agitation. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
dexmedetomidinenalbuphineSugammadexneostigmine
03
Conditions
Emergence agitation (EA)postoperative painpostoperative nausea and vomiting (PONV)bradyarrhythmiahypopnea
Beyond the preview
Go deeper on ChiCTR2400092265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092265.